Itonis Pharmaceuticals and Dr. Charles Hensley Hitting Production Milestones for Protection of Emesyl(TM) Nausea Remedy
(firmenpresse) - LAGUNA HILLS, CA -- (Marketwired) -- 11/18/13 -- Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® cold remedy, are pleased to release their manufacturing update for Emesyl™, the Company's over-the-counter homeopathic product for the relief of nausea.
Since receiving the first order for the manufacturing of Emesyl™, Oasis Health Products has hit some critical production and scale-up milestones.
"The process has been a bit longer than expected but in the long run, over-coming a substantial barrier to entry serves to protect our proprietary formulations in the nausea relief product against competitors' attempts at any improper replications," says Dr. Charles Hensley. "An extremely important key to this product is not only its efficacy but also having the product and its active blends be difficult for competitors to duplicate. By working closely with the manufacturer, we have been able to accomplish this by using a dedicated Rotavap, which has allowed us to scale up our bench formula while keeping the usually water insoluble actives in solution in a way that does not create discomfort in the consumer's the nasal passage."
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
Itonis, Inc. (the "Company") was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit .
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact:
Itonis, Inc.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2013 - 08:50 Uhr
Sprache: Deutsch
News-ID 1284341
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LAGUNA HILLS, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Itonis Pharmaceuticals and Dr. Charles Hensley Hitting Production Milestones for Protection of Emesyl(TM) Nausea Remedy
"
steht unter der journalistisch-redaktionellen Verantwortung von
Itonis, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
